Single-voxel proton brain spectroscopy exam (PROBE/SV) in patients with primary brain tumors.

OBJECTIVE The Single-Voxel Proton Brain Exam (PROBE/SV) is an automated MR spectroscopic technique. The purpose of this study was to investigate the use of PROBE/SV as a diagnostic tool in patients with primary brain tumors and to compare our findings with the known information obtained from conventional nonautomated MR spectroscopic techniques. SUBJECTS AND METHODS We used PROBE/SV to image 10 normal adults and 46 patients with primary brain tumors: 29 glioblastoma multiformes (GBMs), five anaplastic astrocytomas, and 12 low-grade astrocytomas. All studied were performed on a 1.5-T Signa unit. Average voxel sizes were 6-8 cm3. A corresponding point-resolved spectroscopy spectrum was obtained from normal-appearing brain parenchyma in each patient for comparison with the spectra from known areas of pathology. RESULTS In patients with low-grade gliomas (grades 1 and 2), we observed decreased N-acetylaspartate (12 of 12) and slightly increased choline (11 of 12) when we compared these metabolites with those in the spectra of patients' normal brains. This comparison in patients with GBM yielded markedly decreased N-acetylaspartate (29 of 29) and prominently increased choline (27 of 29). In the short TE spectra, we frequently saw lipid signal in high-grade tumors, especially in GBMs (12 of 20). We identified lactate peaks in high-grade tumors (anaplastic astrocytoma and GBM, 29 of 34) and also in low-grade tumors (four of 12). The creatine signal in all gliomas was slightly less than that of healthy brain tissue. The lowest N-acetylaspartate, choline, and creatinine levels in conjunction with the highest lactate levels were usually found in necrotic portions of high-grade tumors. CONCLUSION PROBE/SV is a simplified MR spectroscopy technique that reduces setup time and provides automatic on-line data processing and display. The voxel location can be selected to focus on the area of interest and to minimize voxel contamination from unwanted tissue. The results from our experimentation with PROBE/SV in patients with brain tumors generally concur with published reports of tumor spectra obtained by conventional MR spectroscopic techniques. The ease and accuracy of this new technique make it a useful clinical tool in differentiating human brain tumor grades.

[1]  P A Bottomley,et al.  Human in vivo NMR spectroscopy in diagnostic medicine: clinical tool or research probe? , 1989, Radiology.

[2]  J. Frahm,et al.  On the interpretation of proton NMR spectra from brain tumours in vivo and in vitro , 1992, NMR in biomedicine.

[3]  J A Frank,et al.  Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. , 1990, Radiology.

[4]  S. Grand,et al.  La spectroscopie 1H: une approche métabolique des tumeurs cérébrales et de leur suivi après irradiation externe , 1997 .

[5]  D. Saunders,et al.  Proton spectroscopy in vivo. , 1993, Magnetic resonance quarterly.

[6]  J. Olesen,et al.  Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis , 1991, Magnetic resonance in medicine.

[7]  G. Sutherland,et al.  Mobile lipids and metabolic heterogeneity of brain tumours as detectable by Ex Vivo 1H MR spectroscopy , 1994, NMR in biomedicine.

[8]  B. Ross,et al.  Added Value of Automated Clinical Proton MR Spectroscopy of the Brain , 1995, Journal of computer assisted tomography.

[9]  Klaus J. Zülch,et al.  Classification of Brain Tumors , 1986 .

[10]  E. Shoubridge,et al.  Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo. Preliminary observations on tumor grading , 1990, NMR in biomedicine.

[11]  G Friedmann,et al.  Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. , 1992, Radiology.

[12]  Ian C. P. Smith,et al.  1H MRS of high grade astrocytomas: Mobile lipid accumulation in necrotic tissue , 1994, NMR in biomedicine.

[13]  W. Heiss,et al.  Positron emission tomography of fluorine-18-deoxyglucose and image-guided phosphorus-31 magnetic resonance spectroscopy in brain tumors. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  B. Ross,et al.  Clinical Applications of Magnetic Resonance Spectroscopy , 1997, Epilepsia.

[15]  H. Bruhn,et al.  Localized high‐resolution proton NMR spectroscopy using stimulated echoes: Initial applications to human brain in vivo , 1989, Magnetic resonance in medicine.

[16]  W. Negendank,et al.  Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.

[17]  S. Naruse,et al.  [The clinical application of multi-voxel 1H-CSI (chemical shift imaging) in brain tumors]. , 1991, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica.

[18]  J. Voges,et al.  In vivo imaging of glucose consumption and lactate concentration in human gliomas , 1992, Annals of neurology.

[19]  S. Ashwal,et al.  1H‐magnetic resonance spectroscopy—determined cerebral lactate and poor neurological outcomes in children with central nervous system disease , 1997, Annals of neurology.

[20]  P G Webb,et al.  Automated single‐voxel proton MRS: Technical development and multisite verification , 1994, Magnetic resonance in medicine.

[21]  François Lazeyras,et al.  Magnetic Resonance in Preterm and Term Newborns: 1H-Spectroscopy in Developing Human Brain , 1991, Pediatric Research.